STOCK TITAN

Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Enovis (NYSE: ENOV) has expanded its EMPOWR Revision Knee™ system with the addition of EMPOWR™ Cones, creating a comprehensive portfolio for complex revision knee surgeries. The FDA-cleared cones include stackable tibial, femoral, and diaphyseal options to treat bone defects. This expansion aims to redefine revision knee arthroplasty by offering a streamlined yet comprehensive setup, reducing operating room clutter while allowing surgeons to fine-tune implant fit.

The system's features include femoral and tibial stackable augments usable both medially and laterally, minimizing excess inventory. Multifunctional instrumentation keeps the surgeon's back table organized, streamlining procedures. The addition of EMPOWR Cones provides surgeons with greater flexibility in tailoring revision surgeries, addressing a market need for more efficient revision options, particularly with growing interest in outpatient procedures.

Loading...
Loading translation...

Positive

  • Expansion of EMPOWR Revision Knee™ system with FDA-cleared EMPOWR™ Cones
  • Comprehensive portfolio for complex revision knee surgeries
  • Streamlined setup reducing operating room clutter
  • Flexible options with stackable augments usable both medially and laterally
  • Addresses market need for more efficient revision options, including outpatient procedures

Negative

  • None.

News Market Reaction 1 Alert

-0.96% News Effect

On the day this news was published, ENOV declined 0.96%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller.

WILMINGTON, DE, Aug. 20, 2024 (GLOBE NEWSWIRE) --  Enovis™ (NYSE: ENOV), an innovation-driven medical technology growth company, announced today the expansion of its EMPOWR Revision Knee™ system to include EMPOWR™ Cones. The addition of the stackable tibial, femoral, and diaphyseal cones increases options for treating bone defects, creating a comprehensive portfolio to support complex revision needs. The FDA cleared use of the EMPOWR™ Cones with EMPOWR Revision Knee™ earlier this year.

The EMPOWR Revision Knee™ system is designed to redefine revision knee arthroplasty through a streamlined yet comprehensive setup which reduces clutter in the operating room while allowing surgeons to fine-tune implant fit to each patient. EMPOWR’s femoral and tibial stackable augments can be used both medially and laterally to minimize excess inventory. The multifunctional instrumentation keeps the surgeon’s back table efficiently organized, streamlining revision procedures.

“The introduction of the EMPOWR Revision Knee fills a current market need for more efficient revision options, especially with growing interest in outpatient revision knee procedures,” said Louie Vogt, Group President of Enovis’ Reconstructive Business Group. “Now with the addition of the EMPOWR Cones, surgeons are better able to tailor revision surgeries with a modernized workflow and no decision fatigue.”

“With the addition of the EMPOWR Cones, I now have the added flexibility to help more patients with their knee revision needs,” said Dr. Leonard T. Buller1, a hip and knee surgeon at Indiana University Health. “The cones were easy to ream, fit as planned, and the dimensions are ideal for accommodating the widest spectrum of implants.”

Following his first use of the implant, Dr. Beau J. Kildow of University of Nebraska Medical Center reported that “It went very smooth. Even the femoral cone prep was simple, more so than the leading competitive brand and sat line to line.”

For more information about EMPOWR Revision Knee™, please visit enovis.com/empowr-revision-knee.

1,2Drs. Kildow and Buller are paid consultants of Enovis.

About Enovis
Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.

Media Contact
Kristen McColpin
Director of Marketing Communications, Enovis Surgical
Kristen.McColpin@enovis.com


FAQ

What new product has Enovis (ENOV) added to its EMPOWR Revision Knee™ system?

Enovis has added EMPOWR™ Cones to its EMPOWR Revision Knee™ system, including stackable tibial, femoral, and diaphyseal cones for treating bone defects in revision knee surgeries.

How does the EMPOWR Revision Knee™ system aim to improve revision knee arthroplasty?

The system aims to redefine revision knee arthroplasty by offering a streamlined yet comprehensive setup, reducing operating room clutter while allowing surgeons to fine-tune implant fit to each patient.

What are the key features of Enovis' (ENOV) EMPOWR Revision Knee™ system?

Key features include femoral and tibial stackable augments usable both medially and laterally, multifunctional instrumentation for efficient organization, and the addition of EMPOWR™ Cones for greater flexibility in treating bone defects.

When did the FDA clear the use of EMPOWR™ Cones with EMPOWR Revision Knee™?

The FDA cleared the use of EMPOWR™ Cones with EMPOWR Revision Knee™ earlier in 2024, as mentioned in the press release dated August 20, 2024.
Enovis Corp

NYSE:ENOV

ENOV Rankings

ENOV Latest News

ENOV Latest SEC Filings

ENOV Stock Data

1.52B
56.28M
1.57%
121.34%
12.07%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WILMINGTON